Effect of high-dose intravenous @entity134 pulse therapy followed by 3-month oral @entity134 therapy for Graves' XXXX .

@entity1 @entity1667 @entity1184 @entity229 @entity134 @entity892 @entity6875
PURPOSE: To evaluate the effect of high-dose intravenous @entity134 pulse therapy followed by 3-month oral @entity134 therapy for Graves' @entity6875 . METHODS: We selected 41 Japanese @entity1 (age range, 21-76 years; mean = 49 years) who had active Graves' @entity6875 among 205 consecutive @entity1 examined at Sapporo Medical University Hospital between 1997 and 1999. In a prospective study, we investigated the effect on the 41 @entity1 of high-dose intravenous @entity1667 pulse therapy (1 g/day x 3 days x 3 times) followed by 3-month oral @entity229 therapy. Coronal computed tomography (CT) of the orbit, exophthalmometry and monocular fixation field measured by Goldmann perimetry were carried out before the @entity134 pulse therapy, and 1 and 6 months after the @entity134 pulse therapy. The maximum coronal section area of the rectus muscle in each eye was measured using an orbital CT image. RESULTS: Extraocular muscle @entity1184 was significantly reduced 1 and 6 months after the pulse therapy (paired t-test, P <.01), and was not significantly different between 1 and 6 months after the pulse therapy. Proptosis was not significantly reduced by the pulse therapy. Monocular fixation fields were measured in 34 @entity1 with @entity892 , and limitation of eye movements was improved in 15 @entity1 (44%) by the pulse therapy. In the other @entity1 , improvement of the limitation was not detectable by the test of the monocular fixation field. CONCLUSIONS: The treatment in this study is effective for extraocular muscle @entity1184 , and relapse was minimum within 6 months. However, this treatment has limited effect on limitation of eye movements and less effect on proptosis.
